These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 8566178)

  • 1. Anti-calmodulin potency of indol alkaloids in in vitro systems.
    Molnár A; Liliom K; Orosz F; Vértessy BG; Ovádi J
    Eur J Pharmacol; 1995 Oct; 291(2):73-82. PubMed ID: 8566178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The interaction of a new anti-tumour drug, KAR-2 with calmodulin.
    Orosz F; Vértessy BG; Salerno C; Crifo C; Capuozzo E; Ovádi J
    Br J Pharmacol; 1997 Jul; 121(5):955-62. PubMed ID: 9222553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of a new bis-indol derivative, KAR-2 with tubulin and its antimitotic activity.
    Orosz F; Kovács J; Löw P; Vértessy BG; Urbányi Z; Acs T; Keve T; Ovádi J
    Br J Pharmacol; 1997 Jul; 121(5):947-54. PubMed ID: 9222552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetic analysis in living cells of the inhibition of the P-glycoprotein-mediated efflux of anthracyclines by vinca alkaloids.
    Pereira E; Tarasiuk J; Garnier-Suillerot A
    Chem Biol Interact; 1998 Jul; 114(1-2):61-76. PubMed ID: 9744556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New semisynthetic vinca alkaloids: chemical, biochemical and cellular studies.
    Orosz F; Comin B; Raïs B; Puigjaner J; Kovács J; Tárkányi G; Acs T; Keve T; Cascante M; Ovádi J
    Br J Cancer; 1999 Mar; 79(9-10):1356-65. PubMed ID: 10188876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of vinca alkaloids with tubulin: a comparison of vinblastine, vincristine, and vinorelbine.
    Lobert S; Vulevic B; Correia JJ
    Biochemistry; 1996 May; 35(21):6806-14. PubMed ID: 8639632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Thermodynamics of calmodulin and tubulin binding to the vinca-alkaloid vinorelbine].
    Tsvetkov FO; Kulikova AA; Devred F; Zerniĭ EIu; Lafitte D; Makarov AA
    Mol Biol (Mosk); 2011; 45(4):697-702. PubMed ID: 21954603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calmodulin, activated cyclic nucleotide phosphodiesterase, microtubules, and vinca alkaloids.
    Watanabe K; West WL
    Fed Proc; 1982 May; 41(7):2292-9. PubMed ID: 6122611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative pharmacokinetics of antitumor Vinca alkaloids: intravenous bolus injections of navelbine and related alkaloids to cancer patients and rats.
    Rahmani R; Guéritte F; Martin M; Just S; Cano JP; Barbet J
    Cancer Chemother Pharmacol; 1986; 16(3):223-8. PubMed ID: 3698163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular docking and pharmacogenomics of vinca alkaloids and their monomeric precursors, vindoline and catharanthine.
    Sertel S; Fu Y; Zu Y; Rebacz B; Konkimalla B; Plinkert PK; Krämer A; Gertsch J; Efferth T
    Biochem Pharmacol; 2011 Mar; 81(6):723-35. PubMed ID: 21219884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dissimilar mechanisms of action of anticalmodulin drugs: quantitative analysis.
    Orosz F; Telegdi M; Liliom K; Solti M; Korbonits D; Ovádi J
    Mol Pharmacol; 1990 Dec; 38(6):910-6. PubMed ID: 2147457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of interaction of vinca alkaloids with tubulin: catharanthine and vindoline.
    Prakash V; Timasheff SN
    Biochemistry; 1991 Jan; 30(3):873-80. PubMed ID: 1988072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the interaction of TZT-1027, a potent antitumor agent, with tubulin.
    Natsume T; Watanabe J; Tamaoki S; Fujio N; Miyasaka K; Kobayashi M
    Jpn J Cancer Res; 2000 Jul; 91(7):737-47. PubMed ID: 10920282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain.
    Bai R; Pettit GR; Hamel E
    Biochem Pharmacol; 1990 Jun; 39(12):1941-9. PubMed ID: 2353935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vinflunine, a novel microtubule inhibitor, suppresses calmodulin interaction with the microtubule-associated protein STOP.
    Makarov AA; Tsvetkov PO; Villard C; Esquieu D; Pourroy B; Fahy J; Braguer D; Peyrot V; Lafitte D
    Biochemistry; 2007 Dec; 46(51):14899-906. PubMed ID: 18052208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibodies to antitumor Vinca alkaloids: thermodynamics and kinetics.
    Pontarotti PA; Rahmani R; Martin M; Barbet J
    Mol Immunol; 1985 Mar; 22(3):277-84. PubMed ID: 4000131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uptake and metabolism of vinca alkaloids by freshly isolated human hepatocytes in suspension.
    Zhou XJ; Placidi M; Rahmani R
    Anticancer Res; 1994; 14(3A):1017-22. PubMed ID: 8074443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Energetics of vinca alkaloid interactions with tubulin isotypes: implications for drug efficacy and toxicity.
    Lobert S; Frankfurter A; Correia JJ
    Cell Motil Cytoskeleton; 1998; 39(2):107-21. PubMed ID: 9484953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aging of tubulin at neutral pH: the destabilizing effect of vinca alkaloids.
    Prakash V; Timasheff SN
    Arch Biochem Biophys; 1992 May; 295(1):137-45. PubMed ID: 1575510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New insights into Vinca alkaloids resistance mechanism and circumvention in lung cancer.
    Zhang Y; Yang SH; Guo XL
    Biomed Pharmacother; 2017 Dec; 96():659-666. PubMed ID: 29035832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.